APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Drugs for the Treatment of Wet AMD

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchAnti-VEGF Drugs for the Treatment of Wet AMD Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-VEGF Drugs for the Treatment of Wet AMD market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-VEGF Drugs for the Treatment of Wet AMD is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD include Chengdu Kanghong Pharmaceutica, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-VEGF Drugs for the Treatment of Wet AMD, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-VEGF Drugs for the Treatment of Wet AMD, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-VEGF Drugs for the Treatment of Wet AMD, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-VEGF Drugs for the Treatment of Wet AMD sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-VEGF Drugs for the Treatment of Wet AMD sales, projected growth trends, production technology, application and end-user industry.

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Company

Chengdu Kanghong Pharmaceutica

Samsung Bioepis

Roche

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Type

Single target Drugs

Multi-target Drugs

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Drugs for the Treatment of Wet AMD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Drugs for the Treatment of Wet AMD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-VEGF Drugs for the Treatment of Wet AMD in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-VEGF Drugs for the Treatment of Wet AMD manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGF Drugs for the Treatment of Wet AMD sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Single target Drugs Major Manufacturers Table 3. Multi-target Drugs Major Manufacturers Table 4. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital and Clinic Major Manufacturers Table 6. Retail Pharmacies Major Manufacturers Table 7. Other Major Manufacturers Table 8. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends Table 9. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers Table 10. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges Table 11. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints Table 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021-2026) Table 16. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2027-2032) Table 17. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026) & (K Units) Table 19. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2027-2032) & (K Units) Table 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021-2026) Table 21. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2027-2032) Table 22. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Manufacturers (2021-2026) Table 26. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers, Product Type & Application Table 30. Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Anti-VEGF Drugs for the Treatment of Wet AMD by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021-2026) Table 37. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2027-2032) Table 38. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 40. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 41. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021-2026) Table 42. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2027-2032) Table 43. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2026) & (US$/Unit) Table 44. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2027-2032) & (US$/Unit) Table 45. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021-2026) Table 49. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2027-2032) Table 50. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 52. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 53. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021-2026) Table 54. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2027-2032) Table 55. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2026) & (US$/Unit) Table 56. Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2027-2032) & (US$/Unit) Table 57. Chengdu Kanghong Pharmaceutica Company Information Table 58. Chengdu Kanghong Pharmaceutica Business Overview Table 59. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 61. Chengdu Kanghong Pharmaceutica Recent Development Table 62. Samsung Bioepis Company Information Table 63. Samsung Bioepis Business Overview Table 64. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 66. Samsung Bioepis Recent Development Table 67. Roche Company Information Table 68. Roche Business Overview Table 69. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 71. Roche Recent Development Table 72. Regeneron Pharmaceuticals Company Information Table 73. Regeneron Pharmaceuticals Business Overview Table 74. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 76. Regeneron Pharmaceuticals Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 81. Novartis Recent Development Table 82. Coherus BioSciences Company Information Table 83. Coherus BioSciences Business Overview Table 84. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 86. Coherus BioSciences Recent Development Table 87. Biocon Biologics Company Information Table 88. Biocon Biologics Business Overview Table 89. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 91. Biocon Biologics Recent Development Table 92. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 95. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 96. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2021-2026) & (US$/Unit) Table 97. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2027-2032) & (US$/Unit) Table 98. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 101. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 102. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2021-2026) & (US$/Unit) Table 103. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2027-2032) & (US$/Unit) Table 104. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 106. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 107. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 108. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 109. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 110. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2021-2026) & (US$/Unit) Table 111. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2027-2032) & (US$/Unit) Table 112. United States Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 113. Canada Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 114. Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 115. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (US$ Million) Table 116. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (US$ Million) Table 117. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 118. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 119. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2021-2026) & (US$/Unit) Table 120. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2027-2032) & (US$/Unit) Table 121. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (US$ Million) Table 122. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (US$ Million) Table 123. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 124. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 125. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2021-2026) & (US$/Unit) Table 126. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2027-2032) & (US$/Unit) Table 127. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 129. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 130. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 131. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 132. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 133. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2021-2026) & (US$/Unit) Table 134. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2027-2032) & (US$/Unit) Table 135. Germany Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 136. France Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 137. U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 138. Italy Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 139. Russia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 140. Spain Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 141. Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 142. Switzerland Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 143. Sweden Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 144. Poland Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 145. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (US$ Million) Table 146. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (US$ Million) Table 147. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 148. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 149. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2021-2026) & (US$/Unit) Table 150. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2027-2032) & (US$/Unit) Table 151. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (US$ Million) Table 152. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (US$ Million) Table 153. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 154. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 155. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2021-2026) & (US$/Unit) Table 156. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2027-2032) & (US$/Unit) Table 157. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (US$ Million) Table 158. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (US$ Million) Table 159. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 160. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 161. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2021-2026) & (US$/Unit) Table 162. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2027-2032) & (US$/Unit) Table 163. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (US$ Million) Table 164. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (US$ Million) Table 165. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 166. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 167. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2021-2026) & (US$/Unit) Table 168. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2027-2032) & (US$/Unit) Table 169. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 173. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 174. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 175. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2021-2026) & (US$/Unit) Table 176. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2027-2032) & (US$/Unit) Table 177. Japan Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 178. South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 179. India Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 180. Australia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 181. Taiwan Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 182. Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 183. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (US$ Million) Table 184. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (US$ Million) Table 185. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 186. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 187. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2021-2026) & (US$/Unit) Table 188. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Type (2027-2032) & (US$/Unit) Table 189. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (US$ Million) Table 190. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (US$ Million) Table 191. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 192. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 193. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2021-2026) & (US$/Unit) Table 194. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Application (2027-2032) & (US$/Unit) Table 195. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 197. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 198. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 199. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 200. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 201. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2021-2026) & (US$/Unit) Table 202. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Country (2027-2032) & (US$/Unit) Table 203. Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 204. Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 205. Chile Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 206. Colombia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 207. Peru Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 208. Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 209. Israel Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 210. UAE Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 211. Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 212. Iran Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 213. Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Table 214. Key Raw Materials Table 215. Raw Materials Key Suppliers Table 216. Anti-VEGF Drugs for the Treatment of Wet AMD Distributors List Table 217. Anti-VEGF Drugs for the Treatment of Wet AMD Customers List Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. Anti-VEGF Drugs for the Treatment of Wet AMD Image Figure 2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Share 2021 VS 2025 VS 2032 Figure 4. Single target Drugs Image Figure 5. Multi-target Drugs Image Figure 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital and Clinic Image Figure 9. Retail Pharmacies Image Figure 10. Other Image Figure 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Figure 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021-2032) Figure 16. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (2021-2032) & (K Units) Figure 17. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales YoY (2021-2032) & (K Units) Figure 20. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales YoY (2021-2032) & (K Units) Figure 21. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Anti-VEGF Drugs for the Treatment of Wet AMD Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales YoY (2021-2032) & (K Units) Figure 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021-2032) Figure 30. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021-2032) Figure 33. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021-2032) Figure 36. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021-2032) Figure 39. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Type (2021-2032) Figure 40. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Type (2021-2032) Figure 41. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Application (2021-2032) Figure 42. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Application (2021-2032) Figure 43. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country (2021-2032) Figure 44. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country (2021-2032) Figure 45. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Type (2021-2032) Figure 46. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Type (2021-2032) Figure 47. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Application (2021-2032) Figure 48. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Application (2021-2032) Figure 49. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country (2021-2032) Figure 50. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country (2021-2032) Figure 51. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Type (2021-2032) Figure 52. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Type (2021-2032) Figure 53. China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Application (2021-2032) Figure 54. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Application (2021-2032) Figure 55. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Type (2021-2032) Figure 56. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Type (2021-2032) Figure 57. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Application (2021-2032) Figure 58. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Application (2021-2032) Figure 59. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country (2021-2032) Figure 60. Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country (2021-2032) Figure 61. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Type (2021-2032) Figure 62. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Type (2021-2032) Figure 63. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Application (2021-2032) Figure 64. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Application (2021-2032) Figure 65. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country (2021-2032) Figure 66. SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales Share by Country (2021-2032) Figure 67. Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Single target Drugs
  • Multi-target Drugs
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chengdu Kanghong Pharmaceutica
  • Samsung Bioepis
  • Roche
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Type
  3. 1.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Single target Drugs
  5. 1.2.3 Multi-target Drugs
  6. 1.3 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Application
  7. 1.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital and Clinic
  9. 1.3.3 Retail Pharmacies
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Anti-VEGF Drugs for the Treatment of Wet AMD Market Dynamics
  1. 2.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends
  2. 2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers
  3. 2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region
  3. 3.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region
  9. 3.4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Manufacturers
  2. 4.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Manufacturers
  6. 4.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers, Product Type & Application
  13. 4.7 Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market CR5 and HHI
  16. 4.8.2 2025 Anti-VEGF Drugs for the Treatment of Wet AMD Tier 1, Tier 2, and Tier 3
5 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Type
  1. 5.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type
  2. 5.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type
  6. 5.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type
6 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Application
  1. 6.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application
  2. 6.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application
  6. 6.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application
7 Company Profiles
  1. 7.1 Chengdu Kanghong Pharmaceutica
  2. 7.1.1 Chengdu Kanghong Pharmaceutica Company Information
  3. 7.1.2 Chengdu Kanghong Pharmaceutica Business Overview
  4. 7.1.3 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  6. 7.1.5 Chengdu Kanghong Pharmaceutica Recent Developments
  7. 7.2 Samsung Bioepis
  8. 7.2.1 Samsung Bioepis Company Information
  9. 7.2.2 Samsung Bioepis Business Overview
  10. 7.2.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  12. 7.2.5 Samsung Bioepis Recent Developments
  13. 7.3 Roche
  14. 7.3.1 Roche Company Information
  15. 7.3.2 Roche Business Overview
  16. 7.3.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  18. 7.3.5 Roche Recent Developments
  19. 7.4 Regeneron Pharmaceuticals
  20. 7.4.1 Regeneron Pharmaceuticals Company Information
  21. 7.4.2 Regeneron Pharmaceuticals Business Overview
  22. 7.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  24. 7.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Coherus BioSciences
  32. 7.6.1 Coherus BioSciences Company Information
  33. 7.6.2 Coherus BioSciences Business Overview
  34. 7.6.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  36. 7.6.5 Coherus BioSciences Recent Developments
  37. 7.7 Biocon Biologics
  38. 7.7.1 Biocon Biologics Company Information
  39. 7.7.2 Biocon Biologics Business Overview
  40. 7.7.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  42. 7.7.5 Biocon Biologics Recent Developments
8 North America
  1. 8.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type
  2. 8.1.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2032)
  5. 8.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application
  6. 8.2.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2032)
  9. 8.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  10. 8.3.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-VEGF Drugs for the Treatment of Wet AMD Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type
  2. 9.1.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2032)
  5. 9.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application
  6. 9.2.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2032)
  9. 9.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  10. 9.3.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type
  2. 10.1.1 China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032)
  4. 10.1.3 China Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2032)
  5. 10.2 China Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application
  6. 10.2.1 China Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032)
  8. 10.2.3 China Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type
  2. 11.1.1 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2032)
  5. 11.2 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application
  6. 11.2.1 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2032)
  9. 11.3 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  10. 11.3.1 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-VEGF Drugs for the Treatment of Wet AMD Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Type
  2. 12.1.1 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Application
  6. 12.2.1 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Market Size by Country
  10. 12.3.1 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-VEGF Drugs for the Treatment of Wet AMD Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Analysis
  2. 13.1.1 Anti-VEGF Drugs for the Treatment of Wet AMD Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process
  6. 13.2 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Distributors
  9. 13.2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst